Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S. Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the ...

Hims & Hers stock jumped 6% in post-market trading Monday after the company said it was in active discussions to make Wegovy injections and Novo Nordisk’s forthcoming obesity pill available through ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

In June, Novo ended a partnership with Hims & Hers that provided access to Wegovy through the pharma's Novocare Pharmacy because Hims & Hers was trying to skirt legal restrictions on compounding ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...

If you only glance at the share price, you might think the Hims & Hers Health ($HIMS) story has lost its spark. The stock has ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Wegovy pens at a Chicago pharmacy. Telehealth company Hims & Hers says that it could be selling the GLP-1 medication on its platform soon. Telehealth company Hims & Hers Health Inc. said late Monday ...